CTOs on the Move

AltPep

www.altpep.com

 
AltPep Corporation is a biomedical startup with a breakthrough approach for diagnosing and treating some of the world`s most intractable diseases: amyloid diseases. We are currently focusing on CNS disorders, in particular Alzheimer`s Disease (AD). We target and seek to neutralize the early toxic oligomers behind these amyloid diseases, which in the case of AD are due to aggregation of the Amyloid-beta peptide (Abeta).
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.altpep.com
  • 100 NE Northlake Way Suite 300
    Seattle, WA USA 98105
  • Phone: N/A

Executives

Name Title Contact Details

Funding

AltPep raised $23.1M on 01/12/2021

Similar Companies

C2N Diagnostics

C2N Diagnostics is a privately-held biotechnology company based in St. Louis, Missouri. We focus on the development of clinical diagnostics and therapeutics for serious brain disorders, with a particular emphasis on Alzheimer`s disease and related forms of progressive neurodegeneration.

BioTek Instruments

BioTek Instruments is a worldwide leader in the development of high performance, bioanalytical measurement systems and software. Our representatives worldwide call on a variety of customers including academic, government, and biotech/pharmaceutical. We

Genewiz Inc

Genewiz Inc is a South Plainfield, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Synaptogenix

Synaptogenix is a clinical-stage biotech company leveraging Bryostatin-1 and its analogues to discover and develop targeted therapeutics for neurodegenerative diseases and developmental disorders.

Genoa Pharmaceuticals Inc

Genoa is a biopharma company committed to developing improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. Our lead asset is inhaled pirfenidone (Aerodone™) for the treatment of IPF. With offices in Seattle and San Diego, Genoa`s experienced clinical and inhaled product development team is rapidly advancing Aerodone for the treatment of IPF and additional pipeline candidates for IPF and other severe respiratory diseases.